Profile of patients receiving intravitreal anti-vascular endothelial growth factor injections during COVID-19-related lockdown
Purpose: The aim of this study was to analyze the impact on vision due to delay in presentation of patients requiring intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections, consequent to COVID-19-related travel restrictions. Methods: Data were collected retrospectively of patie...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
| Series: | Indian Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2021;volume=69;issue=3;spage=730;epage=733;aulast=Sindal |
| _version_ | 1819175724463947776 |
|---|---|
| author | Manavi D Sindal Kanika Chhabra Vaibhav Khanna |
| author_facet | Manavi D Sindal Kanika Chhabra Vaibhav Khanna |
| author_sort | Manavi D Sindal |
| collection | DOAJ |
| description | Purpose: The aim of this study was to analyze the impact on vision due to delay in presentation of patients requiring intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections, consequent to COVID-19-related travel restrictions. Methods: Data were collected retrospectively of patients who received anti-VEGF injections during four months of the COVID-19 pandemic. Visual acuities, indication for treatment were noted along with basic demographic characteristics. Results: Data were analyzed for 303 eyes of 263 patients. The indication for treatment was age-related macular degeneration (AMD) in 60 eyes (19.8%), while 162 eyes (53.5%) had Diabetic Macular Edema, 71 eyes (23.4%) had Retinal Vein Occlusion and 10 eyes (3.3%) had other diagnosis. The visual acuity in the treatment naïve eyes (Group A, n = 168) was significantly worse (P <0.001) than those who presented for retreatment (Group B, n = 135). In Group B, there was a significant decline in vision for the entire cohort (P = 0.009) and those with AMD (P = 0.036). Those in Group B presented at a mean interval of 19.1 ± 10.6 (range, 4–64) weeks for retreatment. Conclusion: The COVID-19 pandemic has led to a delay in patients receiving anti-VEGF injections. The visual acuity is worse in both treatment naïve as well as those requiring retreatment. This could have long-term impact on vision of patients requiring this vision preserving treatment. |
| first_indexed | 2024-12-22T20:59:25Z |
| format | Article |
| id | doaj.art-76a3b5145edb4a64953c8a694c65a1d9 |
| institution | Directory Open Access Journal |
| issn | 0301-4738 1998-3689 |
| language | English |
| last_indexed | 2024-12-22T20:59:25Z |
| publishDate | 2021-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Ophthalmology |
| spelling | doaj.art-76a3b5145edb4a64953c8a694c65a1d92022-12-21T18:12:52ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892021-01-0169373073310.4103/ijo.IJO_2807_20Profile of patients receiving intravitreal anti-vascular endothelial growth factor injections during COVID-19-related lockdownManavi D SindalKanika ChhabraVaibhav KhannaPurpose: The aim of this study was to analyze the impact on vision due to delay in presentation of patients requiring intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections, consequent to COVID-19-related travel restrictions. Methods: Data were collected retrospectively of patients who received anti-VEGF injections during four months of the COVID-19 pandemic. Visual acuities, indication for treatment were noted along with basic demographic characteristics. Results: Data were analyzed for 303 eyes of 263 patients. The indication for treatment was age-related macular degeneration (AMD) in 60 eyes (19.8%), while 162 eyes (53.5%) had Diabetic Macular Edema, 71 eyes (23.4%) had Retinal Vein Occlusion and 10 eyes (3.3%) had other diagnosis. The visual acuity in the treatment naïve eyes (Group A, n = 168) was significantly worse (P <0.001) than those who presented for retreatment (Group B, n = 135). In Group B, there was a significant decline in vision for the entire cohort (P = 0.009) and those with AMD (P = 0.036). Those in Group B presented at a mean interval of 19.1 ± 10.6 (range, 4–64) weeks for retreatment. Conclusion: The COVID-19 pandemic has led to a delay in patients receiving anti-VEGF injections. The visual acuity is worse in both treatment naïve as well as those requiring retreatment. This could have long-term impact on vision of patients requiring this vision preserving treatment.http://www.ijo.in/article.asp?issn=0301-4738;year=2021;volume=69;issue=3;spage=730;epage=733;aulast=Sindalage-related macular degenerationanti-vegfcovid-19diabetic macular edemaretinal vein occlusion |
| spellingShingle | Manavi D Sindal Kanika Chhabra Vaibhav Khanna Profile of patients receiving intravitreal anti-vascular endothelial growth factor injections during COVID-19-related lockdown Indian Journal of Ophthalmology age-related macular degeneration anti-vegf covid-19 diabetic macular edema retinal vein occlusion |
| title | Profile of patients receiving intravitreal anti-vascular endothelial growth factor injections during COVID-19-related lockdown |
| title_full | Profile of patients receiving intravitreal anti-vascular endothelial growth factor injections during COVID-19-related lockdown |
| title_fullStr | Profile of patients receiving intravitreal anti-vascular endothelial growth factor injections during COVID-19-related lockdown |
| title_full_unstemmed | Profile of patients receiving intravitreal anti-vascular endothelial growth factor injections during COVID-19-related lockdown |
| title_short | Profile of patients receiving intravitreal anti-vascular endothelial growth factor injections during COVID-19-related lockdown |
| title_sort | profile of patients receiving intravitreal anti vascular endothelial growth factor injections during covid 19 related lockdown |
| topic | age-related macular degeneration anti-vegf covid-19 diabetic macular edema retinal vein occlusion |
| url | http://www.ijo.in/article.asp?issn=0301-4738;year=2021;volume=69;issue=3;spage=730;epage=733;aulast=Sindal |
| work_keys_str_mv | AT manavidsindal profileofpatientsreceivingintravitrealantivascularendothelialgrowthfactorinjectionsduringcovid19relatedlockdown AT kanikachhabra profileofpatientsreceivingintravitrealantivascularendothelialgrowthfactorinjectionsduringcovid19relatedlockdown AT vaibhavkhanna profileofpatientsreceivingintravitrealantivascularendothelialgrowthfactorinjectionsduringcovid19relatedlockdown |